SEPs could be next in line for investor validity challenges as rumours grow of two big, new funds launching
As we approach the end of the year and consider the main trends of 2015 there’s no doubt that one of the biggest stories has been the IPR challenges to biotech and pharma patents filed by Erich Spangenberg and Kyle Bass. They’re not alone in seeing…
To read more
Register for limited access
Register to receive our weekly newsletter and access two of our subscriber-only articles per month.
Register now
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.
Subscribe now